0001209191-14-003013.txt : 20140113 0001209191-14-003013.hdr.sgml : 20140113 20140113214200 ACCESSION NUMBER: 0001209191-14-003013 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140109 FILED AS OF DATE: 20140113 DATE AS OF CHANGE: 20140113 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SALIX PHARMACEUTICALS LTD CENTRAL INDEX KEY: 0001009356 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943267443 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8510 COLONNADE CENTER DRIVE CITY: RALEIGH STATE: NC ZIP: 27615 BUSINESS PHONE: (919) 862-1000 MAIL ADDRESS: STREET 1: 8510 COLONNADE CENTER DRIVE CITY: RALEIGH STATE: NC ZIP: 27615 FORMER COMPANY: FORMER CONFORMED NAME: SALIX HOLDINGS LTD DATE OF NAME CHANGE: 19970807 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DERBYSHIRE ADAM C CENTRAL INDEX KEY: 0001212669 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23265 FILM NUMBER: 14525585 MAIL ADDRESS: STREET 1: 8540 COLONNADE CENTER DRIVE STREET 2: SUITE 501 CITY: RALEIGH STATE: NC ZIP: 27615 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2014-01-09 0 0001009356 SALIX PHARMACEUTICALS LTD SLXP 0001212669 DERBYSHIRE ADAM C 8510 COLONNADE CENTER DRIVE RALEIGH NC 27615 0 1 0 0 EVP Finance/CFO Common Stock 2014-01-09 4 M 0 30001 18.8733 A 209396 D Common Stock 2014-01-09 4 S 0 2400 91.95 D 206996 D Common Stock 2014-01-09 4 S 0 27601 91.44 D 179395 D Option to Buy Common Stock 18.8733 2014-01-09 4 M 0 30001 0.00 D 2014-06-17 Common Stock 30001 0 D Option to Buy Common Stock 17.63 2015-06-09 Common Stock 20000 20000 D The exercise and sale were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2013. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.91 to $92.03, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.91 to $91.90, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Options are 100% vested. The reporting person's prior Forms 4 mistakenly indicated the total number of derivative securities beneficially owned was 30,000 when in fact the total number of derivative securities beneficially owned is 30,001. The reporting person's transactions and derivative security holdings reported herein reflect the correct information as of the date hereof. /s/ Donald R. Reynolds, by Power of Attorney 2014-01-13